Monitor the Q1 FY2027 earnings release for the first full-quarter results under the new segment structure and for any updates on the strategic alternatives for the Other segment businesses.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 4 $354.00entry
- T+1 · 12d ago −4.05%α +0.36% · $339.68
- T+5 · 6d ago −1.16%α −0.25% · $349.88
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cencora filed an 8-K to disclose a restructuring of its operating model and a new reportable segment structure effective Q1 FY2027. The filing includes unaudited revised segment revenue and operating income data for FY2025 and FY2026 under the new segments: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. This is a routine disclosure of a structural change with no new financial guidance or material impact on overall results.
Key Facts
- Cencora restructured its operating model and reorganized business components within U.S. Healthcare Solutions and International Healthcare Solutions reportable segments.
- New reporting structure effective Q1 FY2027: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other.
- Other segment includes businesses under strategic review: MWI Animal Health, Profarma, and other components of PharmaLex.
- FY2026 total revenue was $337.4 billion, up 5.0% from FY2025 total revenue of $321.3 billion.
- FY2026 total segment operating income was $4.81 billion, up 14.0% from FY2025 total segment operating income of $4.22 billion.
- Pharmaceutical Distribution and Services FY2026 operating income margin was 0.96% vs 0.92% in FY2025.
- Specialty Pharmaceutical and Provider Services FY2026 operating income margin was 3.73% vs 3.22% in FY2025.
Financial Impact
No new financial guidance or material change to overall results; segment reclassification only.
Risk Factors
- The Other segment, which includes businesses under strategic review, had an operating income margin of 4.50% in FY2026, down from 4.31% in FY2025; any divestiture or impairment could affect future results.
- Restructuring execution risk may temporarily impact segment-level performance in the near term.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140859-26-000040 |
| Document: abc-20261104.htm | 0001140859-26-000040 |
| Document: 0001140859-26-000040-index-headers.html | 0001140859-26-000040 |
| Document: 0001140859-26-000040-index.html | 0001140859-26-000040 |
| Document: 0001140859-26-000040.txt | 0001140859-26-000040 |
Track record
12 reports on COR
1 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +6.03% at T+20 after the Aug 5, 2026 report. 1 of 4 went positive at some point.
Filters
- Nov 4, 202612d ago 8-K Neutral 2/10 Viewing Entry $354.00 to $339.68 Now $356.94 +0.83% ▼ −4.05% +0.36% vs SPY
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $354.00 to $339.68 Now $356.94 +0.83% ▼ −4.05% +0.36% vs SPY
- Oct 21, 202626d ago 8-K Bullish 7/10 Entry $340.43 to $338.48 Now $356.94 +4.85% ▼ −0.57% +0.61% vs SPY
- Oct 20, 202627d ago Institutional Cluster Mixed 3/10 Entry $340.43 to $338.48 Now $356.94 +4.85% ▼ −0.57% +0.61% vs SPY
- Sep 25, 20267w ago 8-K Neutral 2/10 Entry $306.92 to $303.81 Now $356.94 +16.30% ▼ −1.01% −0.27% vs SPY
- Aug 21, 202612w ago Institutional Cluster Mixed 6/10 Entry $318.04 to $323.77 Now $356.94 +12.23% ▲ +1.80% +2.10% vs SPY
- Aug 5, 202614w ago 8-K Neutral 3/10 Entry $317.22 to $325.01 Now $356.94 +12.52% ▲ +2.46% +2.62% vs SPY
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $317.22 to $325.01 Now $356.94 +12.52% ▲ +2.46% +2.62% vs SPY
- Jun 15, 202622w ago 8-K Neutral 2/10 Entry $281.46 to $277.09 Now $356.94 +26.82% ▼ −1.55% −0.30% vs SPY
- May 29, 202624w ago 8-K Neutral 3/10 Entry $264.69 to $264.84 Now $356.94 +34.85% ▲ +0.06% −0.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers